Literature DB >> 17713307

Treating the whole patient for optimal management of type 2 diabetes: considerations for insulin therapy.

Carlos Campos1.   

Abstract

Primary care physicians are responsible for providing healthcare to most patients with type 2 diabetes. In this role, it is critical that physicians utilize a whole-patient treatment approach that includes lifestyle modifications and pharmacotherapy aimed to achieve glycemic control, in addition to the management of any comorbid conditions or risk factors for cardiovascular complications of diabetes. Due to the progressive nature of the disease, most patients with type 2 diabetes will eventually require insulin to achieve and maintain glycemic control, because of both increased insulin resistance and diminished secretory capacity of the pancreatic beta cells. Thus, physicians need to be knowledgeable about and comfortable with the use of insulin, as well as with educating patients and discussing any potential barriers to insulin therapy. The use of a stepwise approach--beginning with basal insulin therapy and adding prandial insulin if necessary--is simple, effective, and appropriate for use in many patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17713307     DOI: 10.1097/SMJ.0b013e3180485a9d

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

1.  An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care.

Authors:  J MacMahon Tone; A Agha; M Sherlock; F Finucane; W Tormey; C J Thompson
Journal:  Ir J Med Sci       Date:  2009-04-15       Impact factor: 1.568

2.  Long segment ileal transposition leads to early amelioration of glucose control in the diabetic obese Zucker rat.

Authors:  Jodok Matthias Grueneberger; Tobias Fritz; Cheng Zhou; Sebastian Meyer; Iwona Karcz-Socha; Tomasz Sawczyn; Dominica Stygar; Matthias Goos; Ulrich Theodor Hopt; Simon Küsters
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2013-01-21       Impact factor: 1.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.